Trispecific natural killer cell nanoengagers for targeted chemoimmunotherapy
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Trispecific natural killer cell nanoengagers for targeted chemoimmunotherapy
Authors
Keywords
-
Journal
Science Advances
Volume 6, Issue 27, Pages eaba8564
Publisher
American Association for the Advancement of Science (AAAS)
Online
2020-07-04
DOI
10.1126/sciadv.aba8564
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pretargeted delivery of PI3K/mTOR small-molecule inhibitor–loaded nanoparticles for treatment of non-Hodgkin’s lymphoma
- (2020) Kin Man Au et al. Science Advances
- Cancer statistics, 2019
- (2019) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Bespoke Pretargeted Nanoradioimmunotherapy for the Treatment of Non-Hodgkin Lymphoma
- (2018) Kin Man Au et al. ACS Nano
- CAR T-cell Therapy: A New Era in Cancer Immunotherapy
- (2018) Miliotou N. Androulla et al. CURRENT PHARMACEUTICAL BIOTECHNOLOGY
- CAR T Cells in Trials: Recent Achievements and Challenges that Remain in the Production of Modified T Cells for Clinical Applications
- (2018) Ulrike Köhl et al. HUMAN GENE THERAPY
- Chimeric Antigen Receptor Therapy
- (2018) Carl H. June et al. NEW ENGLAND JOURNAL OF MEDICINE
- CAR T Cells in Solid Tumors: Blueprints for Building Effective Therapies
- (2018) Hannah M. Knochelmann et al. Frontiers in Immunology
- A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity
- (2018) Marta Compte et al. Nature Communications
- High-Performance Concurrent Chemo-Immuno-Radiotherapy for the Treatment of Hematologic Cancer through Selective High-Affinity Ligand Antibody Mimic-Functionalized Doxorubicin-Encapsulated Nanoparticles
- (2018) Kin Man Au et al. ACS Central Science
- Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape
- (2017) Leisha A. Emens et al. EUROPEAN JOURNAL OF CANCER
- Potentiation of Natural Killer Cells for Cancer Immunotherapy: A Review of Literature
- (2017) Lacy E. Lowry et al. Frontiers in Immunology
- The Molecular Mechanism of Natural Killer Cells Function and Its Importance in Cancer Immunotherapy
- (2017) Sourav Paul et al. Frontiers in Immunology
- Abscopal Effects of Radiotherapy Are Enhanced by Combined Immunostimulatory mAbs and Are Dependent on CD8 T Cells and Crosspriming
- (2016) M. E. Rodriguez-Ruiz et al. CANCER RESEARCH
- CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer
- (2016) Raghvendra M. Srivastava et al. CLINICAL CANCER RESEARCH
- IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function
- (2016) D. A. Vallera et al. CLINICAL CANCER RESEARCH
- Erratum: The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
- (2016) Danny N. Khalil et al. Nature Reviews Clinical Oncology
- TriKEs and BiKEs join CARs on the cancer immunotherapy highway
- (2016) Szun Szun Tay et al. Human Vaccines & Immunotherapeutics
- Toxicity and management in CAR T-cell therapy
- (2016) Challice L Bonifant et al. Molecular Therapy-Oncolytics
- Generation of Highly Cytotoxic Natural Killer Cells for Treatment of Acute Myelogenous Leukemia Using a Feeder-Free, Particle-Based Approach
- (2015) Jeremiah L. Oyer et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection
- (2015) W. Deng et al. SCIENCE
- The endosomal-lysosomal system: from acidification and cargo sorting to neurodegeneration
- (2015) Yong-Bo Hu et al. Translational Neurodegeneration
- CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets
- (2014) M. K. Gleason et al. BLOOD
- Therapeutic potential of highly cytotoxic natural killer cells for gastric cancer
- (2014) Kousaku Mimura et al. INTERNATIONAL JOURNAL OF CANCER
- Targeting CD137 enhances the efficacy of cetuximab
- (2014) Holbrook E. Kohrt et al. JOURNAL OF CLINICAL INVESTIGATION
- Localized Immunotherapy via Liposome-Anchored Anti-CD137 + IL-2 Prevents Lethal Toxicity and Elicits Local and Systemic Antitumor Immunity
- (2013) B. Kwong et al. CANCER RESEARCH
- Molecular mechanisms of natural killer cell activation in response to cellular stress
- (2013) C J Chan et al. CELL DEATH AND DIFFERENTIATION
- Acidic tumor microenvironment downregulates hMLH1 but does not diminish 5-fluorouracil chemosensitivity
- (2013) Moriya Iwaizumi et al. MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS
- Cancer Immunotherapy
- (2013) J. Couzin-Frankel SCIENCE
- Natural Innate and Adaptive Immunity to Cancer
- (2011) Matthew D. Vesely et al. Annual Review of Immunology
- Cancer immunotherapy comes of age
- (2011) Ira Mellman et al. NATURE
- Cytotoxicity of Activated Natural Killer Cells against Pediatric Solid Tumors
- (2010) D. Cho et al. CLINICAL CANCER RESEARCH
- Human natural killer cells
- (2008) M. A. Caligiuri BLOOD
- Fc-dependent expression of CD137 on human NK cells: insights into "agonistic" effects of anti-CD137 monoclonal antibodies
- (2008) W. Lin et al. BLOOD
- Functions of natural killer cells
- (2008) Eric Vivier et al. NATURE IMMUNOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now